Navigation Links
4F Infiniti

Products4F Infiniti
Company Cordis Corporation
Item 4F Infiniti
Features Three-stage braided nylon construction: body (stage 1): braided nylon for torque reponsiveness and stability, proximal segment (stage 2): non-braided nylon for maximum flexibility and shape retention, distal tip (stage 3): soft, radiopaque nylon for minimally cannulation.
Description Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box.
Info Cordis Corporation
Customer Service: (800) 327-7714
Web site: http://www.cordis.com/

Related medicine products :

1. 5F Infiniti
2. 6F Infiniti
TAG: Infiniti
Breaking Medicine Technology:Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 2Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 3The Michael J Fox Foundation Announces 241 5 Million in Funding to Advance Development of Drug Targets for Disease Modifying Parkinsons Disease Trea 15002 1The Michael J Fox Foundation Announces 241 5 Million in Funding to Advance Development of Drug Targets for Disease Modifying Parkinsons Disease Trea 15002 2The Michael J Fox Foundation Announces 241 5 Million in Funding to Advance Development of Drug Targets for Disease Modifying Parkinsons Disease Trea 15002 3SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 1SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 2SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 3SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 4Coverage of inexpensive drugs may increase length and quality of life after heart attack 62268 1Coverage of inexpensive drugs may increase length and quality of life after heart attack 62268 2